Grifolic acid causes osteosarcoma cell death in vitro and in tumor-bearing mice
| Autor: | Zhao Yanyan, Su Xingli, Feng Jiang, Wei Lanlan, Yun-Sheng Hu, Qiong Ma, Liang Xiangyan, Yufeng Zhao |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
musculoskeletal diseases 0301 basic medicine Programmed cell death Sesterterpenes Cell Survival Cell Mice Nude Antineoplastic Agents Bone Neoplasms Mitochondrion Blood cell 03 medical and health sciences 0302 clinical medicine Cell Line Tumor medicine Albatrellus confluens Animals Humans Membrane Potential Mitochondrial Pharmacology Osteosarcoma Dose-Response Relationship Drug biology Chemistry General Medicine biology.organism_classification medicine.disease Xenograft Model Antitumor Assays 030104 developmental biology medicine.anatomical_structure Cell culture 030220 oncology & carcinogenesis Toxicity Cancer research |
| Zdroj: | Biomedicine & Pharmacotherapy. 103:1035-1042 |
| ISSN: | 0753-3322 |
| DOI: | 10.1016/j.biopha.2018.04.132 |
| Popis: | Grifolic acid is a natural compound isolated from the fungus Albatrellus confluens. In the present study, we assessed the effects of grifolic acid on human osteosarcoma cells. We found that grifolic acid dose- and time-dependently induced cell death in the U-2 OS, MG-63, Saos-2, and 143B human osteosarcoma cell lines. Grifolic acid decreased osteosarcoma cell mitochondrial membrane potential, ATP production, and cellular NADH levels, but did not impact mitochondrial membrane potential in isolated mitochondria from human osteosarcoma cells. Intratumoral injection of grifolic acid also promoted tumor cell death and prolonged survival in nude mice bearing human osteosarcoma xenografts. Grifolic acid had no obvious toxicity in mice, with no histological changes in liver, kidney, lung, or heart, and no changes in blood cell counts or levels of plasma total protein, alanine aminotransferase, or aspartate aminotransferase. These results show that grifolic acid induces osteosarcoma cell death by inhibiting NADH generation and ATP production without obvious toxicity. Intratumoral injection of grifolic acid may be a promising anti-osteosarcoma therapeutic option in patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect